Joseph Kim, Inovio CEO (Andrew Harnik, AP Images)
April 23, 2021 10:27 AM EDTUpdated 10:49 AM
Coronavirus

In­ovio's Covid-19 vac­cine stud­ies just hit a brick wall at the Pen­ta­gon. Are oth­er hope­fuls in trou­ble?

Max Gelman

Senior Editor

In­ovio re­ceived some harsh news from the Pen­ta­gon on Fri­day re­gard­ing its Covid-19 vac­cine pro­gram, and it could prove fore­bod­ing to oth­er mid-stage play­ers in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times